中国髋部脆性骨折术后抗骨质疏松药物临床干预指南(2023年版)

Clinical intervention guideline for using of anti-osteoporosis drugs in postoperative fragile hip fractures in China(2023 Edition)

髋部骨质疏松骨折(或称髋部脆性骨折)是指髋部受到轻微创伤即发生的骨折,是骨质疏松症的严重后果之一,也是老年人常见的骨折类型。近年来我国髋部脆性骨折发生率呈显著上升趋势,因其致残率和死亡率高给临床医生带来巨大挑战。髋部脆性骨折手术治疗方式常用内固定术或髋关节置换术。然而,髋部脆性骨折术后如果没有及时正确诊断并给予规范、有效、全程的抗骨质疏松治疗,容易出现再发骨折和假体松动风险。针对患者的特定风险和健康状况制定个体化的治疗方案,及时正确使用抗骨质疏松药物,是减少术后并发症的关键。本指南旨在提供髋部脆性骨折术后的抗骨质疏松药物选择和管理的临床指导,以帮助临床医生更加合理地选择药物治疗方案,有助于髋部骨折术后患者尽早临床愈合,减少卧床时间,降低再骨折及假体松动的发生率。

Hip osteoporosis fracture(also known as hip brittle fracture)refers to a fracture that occurs after minor trauma resulted from a serious consequence of osteoporosis.Hip fracture is also a common type of fracture in the elderly.In recent years,the incidence of hip fracture in China has shown a significant upward trend.The surgical treatment methods for elderly hip fractures commonly include internal fixation or hip joint replacement.However,if osteoporosis hip fractures are not diagnosed correctly in time and receive standardized,effective,and comprehensive anti osteoporosis treatment after surgery,there would be a great risk of re-fracture and prosthesis loosening.Therefore,developing personalized treatment plans target to the specific risks and health status of patients and using of anti osteoporosis drugs timely and correctly are key to reducing postoperative complications.This guideline aims to provide clinical guidance on the selection and management of anti-osteoporosis drugs after osteoporosis hip fracture surgery,help clinician to choose drug treatment plans more reasonably,help patients with hip fracture surgery to recover as soon as possible,reduce bedridden time,and reduce the incidence of re-fracture and prosthesis loosening.